Northwestern University Feinberg School of Medicine

Wainwright Laboratory of Tumor- and Neuro-immunology

News and Events

Please join us for the 2017 Northwestern Brain Tumor Institute Symposium.

Dr. Wainwright joins world-renown pediatric brain tumor immunotherapists to discuss cutting-edge research for children with brain cancer.

Please join us Thursday, February 16th, for the Inaugural Cancer Immunology Working Group Meeting led by Drs. Sosman and Wainwright.

Congratulations Dr. Lijie Zhai, PhD, for acceptance of his manuscript, 'Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma'.

Please join us on Wednesday, January 18th as Dr. Wainwright presents clinical trial data for immunotherapy of primary brain tumors in Developmental Therapeutics Program Grand Rounds.

Congratulations to Drs. Kristen Lauing, PhD, and Alicia Lenzen, MD! Their hard work investigating pediatric high-grade glioma has been awarded a large grant by the Curing Kids Cancer Foundation.

Congratulations to the Wainwright Laboratory for being awarded a 2017 Dixon Translational Research Grant for research entitled 'Investigating the Immunotherapeutic Potential of Esophageal Cancer’.

Please join us at the 2016 Society for Immunotherapy of Cancer Meeting where Dr. Wainwright will present updates on the role of IDO1 in human glioblastoma.

Congratulations to Dr. Erik Ladomersky, PhD, for receiving a Postdoctoral Fellowship award from the Chicago Cancer Baseball Charities!

Congratulations Dr. Lijie Zhai for receiving the Katten Muchin Rosenman Travel Scholarship for your work on identifying IDO1 as a prognostic factor in GBM patients!

Congratulations to the Wainwright Laboratory for being awarded a Clinic and Laboratory Integration Programgrant from a preeminent Cancer Immunotherapy research organization:The Cancer Research Institute (CRI)! The research is entitled ‘IDO1 in glioblastoma: Translating work from mouse to man’, and has been awarded ‘in recognition of the outstanding quality and promise of your (Wainwright Lab’s) research’.

Congratulations to Erik Ladomersky, PhD, for his work being awarded Acceleration Funds from the Robert H. Lurie Comprehensive Cancer Center to expand his translational work using pharmaceutical-grade IDO1 inhibitors against malignant glioma!

Congratulations to Alicia Lenzen, MD, for being awarded a TL1 Multidisciplinary Training Program in Child and Adolescent Health from the Northwestern University Clinical and Translational Sciences (NUCATS) Institute. The award is for her research in developing a nanotherapeutic approach targeting immunosuppressive IDO1 for treatment of children with high grade glioma. 

Congratulations to the Wainwright Laboratory for being awarded their first R01 research grant entitled, “IDO1 and Immunotolerance in Glioblastoma”, from the NIH/National Institute of Neurological Disorders and Stroke

In collaboration with Drs. Chad Mirkin, Bin Zhang and Alex Stegh, the Wainwright Laboratory has been awarded funds through the IDP/ Sherman Fairchild Research Award to develop nanotherapy targeted at human IDO1 for treatment of glioblastoma.

Profile of Matthew Genet and his Student Research Fellowship award by the Alpha Omega Alpha medical honor society, for his research on the role of the protein IDO1 in human glioblastoma with the Wainwright Lab

Congratulations Lijie Zhai on being awarded 2ndPlace in the 2016 Yao Yuan Biotech-Pharma Symposium for his Poster Presentation entitled, ‘Interactions between IDO1 and immune checkpoint blockade in a model of glioblastoma’

Congratulations Matthew Genet on being selected as a 2016 Research Grant Program recipient by the American Medical Association!

Congratulations Matthew Genet on being selected by Northwestern School of Medicine to submit an application to the National Honor Medical Society!

Please attend the upcoming Microbiology-Immunology Departmental seminar on Thursday, February 11 (2:00-3:00pm) to hear updates regarding novel IDO1 functions and immunotherapeutic targeting in glioblastoma.

Please join us at the upcoming 2016 Northwestern Brain Tumor Institute CME Symposium on April 1st, 2016, between 7:15am-3:00pm.

A recent gift from Curing Kids Cancerand the Lurie Children’s Hospital pediatric neuro-oncologists, Drs. Fangusaro and Lulla, will support Kristen Lauing’s work to investigate IDO1 in human pediatric brain tumors.

The work of Derek Wainwright, PhD, 'Targeting Immunosuppression in Brain Tumors' featured in Feinberg School of Medicine News. His lab studies strategies to reverse pathways that inhibit the immune system from fighting glioblastoma.

Dr. Wainwright discusses immunotherapeutically targeting IDO1 in patients with glioblastoma at the 2015 Annual American Neurology Association Meeting.

Please join us at the upcoming 2015 Northwestern Brain Tumor Institute CME Symposium on March 27th, 2015: please click here for more details regarding this event.

Dr. Wainwright will be speaking at the upcoming meeting, Immune Checkpoint Inhibitors: Validating Novel Pathways, Discovering Predictive Biomarkers and Optimizing Clinical Strategy, March 24-26, 2015 in Boston

Join us at the 7th Annual Illinois Brain, Behavior and Immunity Meeting, Friday, January 9th, and Saturday, January 10th, 2015.

Congratulations to Rebecca Angoyar for being awarded a Weinberg College Summer Research Grant!

Dr. Wainwright, in collaboration with the pediatric neurosurgeon, Dr. Amanda Saratsis, MD, and the pediatric neuro-oncologists of the Ann & Robert H. Lurie Children’s Hospital, were invited to write a full application to the Solving Kid’s Cancer/Ty Louis Campbell Foundation(s) to fund a clinical trial for a new and highly promising immunotherapy using the patient’s own immune system to fight incurable brain tumors.

Dr. Wainwright speaks about why brain tumor immunity fails during the upcoming Translational Research in Solid Tumors Program meeting.